173 related articles for article (PubMed ID: 30246377)
1. UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan.
Kimura K; Yamano T; Igeta M; Imada A; Jihyung S; Babaya A; Hamanaka M; Kobayashi M; Tsukamoto K; Noda M; Ikeda M; Tomita N
Cancer Sci; 2018 Dec; 109(12):3934-3942. PubMed ID: 30246377
[TBL] [Abstract][Full Text] [Related]
2. A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1).
Sato T; Hayakawa K; Tomita N; Noda M; Kamikonya N; Watanabe T; Kato D; Sakai Y; Hiraoka M; Shimada M; Ikushima H; Baba H; Oya N; Oya M; Nemoto-Murofushi K; Takeuchi M; Watanabe M
Radiother Oncol; 2016 Aug; 120(2):222-7. PubMed ID: 27317556
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II Study of Preoperative Chemoradiotherapy With TEGAFIRI for Locally Advanced Rectal Cancer.
Kawai K; Sunami E; Hata K; Tanaka T; Nishikawa T; Otani K; Sasaki K; Nozawa H
Clin Colorectal Cancer; 2018 Sep; 17(3):240-246. PubMed ID: 29934092
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Chemotherapy Completion on the Efficacy of Irinotecan in the Preoperative Chemoradiotherapy of Locally Advanced Rectal Cancer: An Expanded Analysis of the CinClare Phase III Trial.
Wang J; Fan J; Li C; Yang L; Wan J; Zhang H; Zhang Z; Zhu J
Clin Colorectal Cancer; 2020 Jun; 19(2):e58-e69. PubMed ID: 32265117
[TBL] [Abstract][Full Text] [Related]
5. Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer.
Zhu J; Li X; Shen Y; Guan Y; Gu W; Lian P; Sheng W; Cai S; Zhang Z
Radiother Oncol; 2018 Oct; 129(1):143-148. PubMed ID: 29273261
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
Nakamura T; Yamashita K; Sato T; Ema A; Naito M; Watanabe M
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):547-55. PubMed ID: 24929164
[TBL] [Abstract][Full Text] [Related]
7. A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate.
Sato T; Ozawa H; Hatate K; Onosato W; Naito M; Nakamura T; Ihara A; Koizumi W; Hayakawa K; Okayasu I; Yamashita K; Watanabe M
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):677-83. PubMed ID: 21035953
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer.
Sato T; Kokuba Y; Koizumi W; Hayakawa K; Okayasu I; Watanabe M
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1442-7. PubMed ID: 17855009
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study).
Ishiguro H; Saji S; Nomura S; Tanaka S; Ueno T; Onoue M; Iwata H; Yamanaka T; Sasaki Y; Toi M
Cancer Med; 2017 Dec; 6(12):2909-2917. PubMed ID: 29131533
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.
Otsuka H; Fujii T; Toh U; Iwakuma N; Takahashi R; Mishima M; Takenaka M; Kakuma T; Tanaka M; Shirouzu K
Breast Cancer; 2015 Jul; 22(4):335-42. PubMed ID: 23827973
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.
Park SR; Kong SY; Rhee J; Park YI; Ryu KW; Lee JH; Kim YW; Choi IJ; Kim CG; Lee JY; Cho SJ; Kim NK
Ann Oncol; 2011 Apr; 22(4):890-896. PubMed ID: 20860988
[TBL] [Abstract][Full Text] [Related]
12. Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by
Zhu J; Liu A; Sun X; Liu L; Zhu Y; Zhang T; Jia J; Tan S; Wu J; Wang X; Zhou J; Yang J; Zhang C; Zhang H; Zhao Y; Cai G; Zhang W; Xia F; Wan J; Zhang H; Shen L; Cai S; Zhang Z
J Clin Oncol; 2020 Dec; 38(36):4231-4239. PubMed ID: 33119477
[TBL] [Abstract][Full Text] [Related]
13. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
[TBL] [Abstract][Full Text] [Related]
14. Transcatheter rectal arterial chemoembolization with oxaliplatin plus S-1 concurrent chemoradiotherapy can improve the pathological remission rate in locally advanced rectal cancer: a comparative study.
Yang B; Shan J; Feng Y; Dai N; Li M; Chen C; He S; Wang G; Xiao H; Li C; Wang D
Radiat Oncol; 2020 May; 15(1):94. PubMed ID: 32375814
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer.
Jung M; Shin SJ; Koom WS; Jung I; Keum KC; Hur H; Min BS; Baik SH; Kim NK; Kim H; Lim JS; Hong SP; Kim TI; Roh JK; Park YS; Ahn JB
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1015-22. PubMed ID: 26581140
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of preoperative chemoradiotherapy with S-1 alone for locally advanced rectal cancer.
Imano N; Murakami Y; Kubo K; Kawahara D; Takeuchi Y; Nishibuchi I; Kimura T; Kochi M; Takakura Y; Shimizu W; Egi H; Uegami S; Ohge H; Takahashi S; Ohdan H; Nagata Y
J Radiat Res; 2021 Mar; 62(2):300-308. PubMed ID: 33341902
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis.
Ohue M; Hamaguchi T; Ito Y; Sakai D; Noura S; Kinugasa Y; Fujita S; Shimada Y; Saito N; Moriya Y
Int J Clin Oncol; 2015 Apr; 20(2):338-44. PubMed ID: 24839048
[TBL] [Abstract][Full Text] [Related]
18. Preoperative radiotherapy combined with S-1 for advanced lower rectal cancer: phase I trial.
Morimoto S; Shimada M; Kurita N; Sato H; Iwata T; Nishioka M; Yoshikawa K; Miyatani T; Kashihara H; Takasu C; Ikushima H
Hepatogastroenterology; 2012; 59(117):1428-32. PubMed ID: 22155856
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial).
Kondo K; Matsusaka S; Ishihara S; Horie H; Uehara K; Oguchi M; Murafushi K; Ueno M; Mizunuma N; Shimbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Fujii M; Nakajima T
Radiother Oncol; 2019 May; 134():199-203. PubMed ID: 31005216
[TBL] [Abstract][Full Text] [Related]
20. UGT1A1 genotype-guided irinotecan dosing during neoadjuvant chemoradiotherapy for locally advanced rectal cancer: A prospective analysis of SN-38 concentration.
Jiang PC; Wang SW; Li C; Fan J; Zhu J
Int J Cancer; 2024 Apr; 154(8):1484-1491. PubMed ID: 38158593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
